Jacobs Levy Equity Management’s BioDelivery Sciences International, Inc. BDSI Stock Holding History

Jacobs Levy Equity Management’s Portfolio BDSI Stock Details BDSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-252,584	Closed	-$783K	–	1145
2021 Q4	$783K	Buy	+252,584	New	+$850K	0.01%	778
2018 Q2	–	Sell	-153,970	Closed	-$346K	–	1171
2018 Q1	$346K	Sell	153,970 -216,246	-58%	-$506K	0.01%	842
2017 Q4	$1.09M	Buy	370,216 +150,347	+68%	+$416K	0.02%	598
2017 Q3	$649K	Buy	219,869 +19,820	+10%	+$60.4K	0.01%	664
2017 Q2	$560K	Buy	+200,049	New	+$422K	0.01%	678
2013 Q3	–	Sell	-20,100	Closed	-$82K	–	1125
2013 Q2	$82K	Buy	+20,100	New	+$94.3K	﹤0.01%	943

Other funds holding BDSI

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

FCMT

Founders Capital Management (Texas) Houston, Texas $205M AUM 41.7% 1-Year Est. Return

Jacobs Levy Equity Management's BDSI Position: Q1 2022 in Review

Jacobs Levy Equity Management sold out of BioDelivery Sciences International, Inc. (BDSI) in Q1 2022, closing a stake of 252,584 shares — an estimated $783K sold.

Jacobs Levy Equity Management first reported a position in BDSI in Q2 2013 and held it in 6 quarters. The position peaked at $1.09M in Q4 2017. 2 funds tracked by Wall St. Rank hold BDSI as of Q1 2022.

Jacobs Levy Equity Management reported no remaining BioDelivery Sciences International, Inc. position as of Q1 2022 after selling out during the quarter.
Jacobs Levy Equity Management sold 252,584 BioDelivery Sciences International, Inc. shares in Q1 2022, an estimated $783K.
Jacobs Levy Equity Management first reported a position in BioDelivery Sciences International, Inc. in Q2 2013 and held it in 6 quarters.
Jacobs Levy Equity Management's BioDelivery Sciences International, Inc. position peaked at $1.09M in Q4 2017.
2 funds tracked by Wall St. Rank held BioDelivery Sciences International, Inc. as of Q1 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2022, filed 16 May 2022.